Posted by Michael Wonder on 26 Aug 2021
Forxiga approved in Japan for the treatment of chronic kidney disease in patients with and without type 2 diabetes
26 August 2021 - Approval marks an important transformation in the treatment of more than 13 million people suffering from chronic kidney disease in Japan.
AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose co-transporter 2 inhibitor, has been approved in Japan for the treatment of chronic kidney disease in adults with and without type 2 diabetes mellitus.
